PE20090047A1 - Anticuerpo recombinante humanizado anti-interleuquina 10 - Google Patents
Anticuerpo recombinante humanizado anti-interleuquina 10Info
- Publication number
- PE20090047A1 PE20090047A1 PE2008001585A PE2008001585A PE20090047A1 PE 20090047 A1 PE20090047 A1 PE 20090047A1 PE 2008001585 A PE2008001585 A PE 2008001585A PE 2008001585 A PE2008001585 A PE 2008001585A PE 20090047 A1 PE20090047 A1 PE 20090047A1
- Authority
- PE
- Peru
- Prior art keywords
- human
- sequence
- germinal
- residue
- humanized antibody
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
SE REFIERE A UN METODO PARA IDENTIFICAR UNA SECUENCIA DE LINEA GERMINAL ACEPTORA PARA UN ANTICUERPO HUMANIZADO, QUE COMPRENDE: A) IDENTIFICAR UN ANTICUERPO NO HUMANO; B) DETERMINAR LA SECUENCIA DE AMINOACIDOS DE LOS DOMINIOS DE LA CADENA PESADA VARIABLE (VH) Y DE LA CADENA LIGERA VARIABLE (VL) DEL ANTICUERPO NO HUMANO; C) COMPARAR LA SECUENCIA DEL ANTICUERPO NO HUMANO CON UN GRUPO DE SECUENCIAS DE LINEAS GERMINALES HUMANAS QUE COMPRENDE i) ASIGNAR NUMEROS DE RESIDUOS A LAS SECUENCIAS DE DOMINIOS VH Y VL NO HUMANAS; ii) DELINEAR LAS REGIONES CDR Y FR EN LA SECUENCIA; iii) ASIGNAR UN RESULTADO NUMERICO PREDETERMINADO EN CADA POSICION DEL RESIDUO PARA LA CUAL LAS SECUENCIAS DE LINEA GERMINAL NO HUMANA Y HUMANA SON IDENTICAS; Y iv) TOTALIZAR TODOS LOS RESULTADOS DE RESIDUOS PARA GENERAR UN RESULTADO TOTAL PARA CADA SECUENCIA DE LINEA GERMINAL HUMANA; Y D) IDENTIFICAR LA SECUENCIA DE LINEA GERMINAL HUMANA CON EL RESULTADO DE RESIDUOS TOTAL MAS ALTO COMO LA SECUENCIA DE LINEA GERMINAL ACEPTORA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51899903P | 2003-11-10 | 2003-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090047A1 true PE20090047A1 (es) | 2009-01-26 |
Family
ID=34590335
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001585A PE20090047A1 (es) | 2003-11-10 | 2004-11-08 | Anticuerpo recombinante humanizado anti-interleuquina 10 |
| PE2004001085A PE20050925A1 (es) | 2003-11-10 | 2004-11-08 | Anticuerpo recombinante humanizado anti-interleuquina 10 |
| PE2008001584A PE20090046A1 (es) | 2003-11-10 | 2004-11-08 | Anticuerpo recombinante humanizado anti-interleuquina 10 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001085A PE20050925A1 (es) | 2003-11-10 | 2004-11-08 | Anticuerpo recombinante humanizado anti-interleuquina 10 |
| PE2008001584A PE20090046A1 (es) | 2003-11-10 | 2004-11-08 | Anticuerpo recombinante humanizado anti-interleuquina 10 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20050101770A1 (es) |
| EP (4) | EP1694705B1 (es) |
| JP (4) | JP4762148B2 (es) |
| KR (3) | KR20120025618A (es) |
| CN (2) | CN102010471A (es) |
| AR (3) | AR046833A1 (es) |
| AT (1) | ATE440867T1 (es) |
| AU (2) | AU2004290044B2 (es) |
| CA (2) | CA2545255C (es) |
| CY (1) | CY1110557T1 (es) |
| DE (1) | DE602004022855D1 (es) |
| DK (1) | DK1694705T3 (es) |
| ES (1) | ES2329907T3 (es) |
| HR (1) | HRP20090517T1 (es) |
| IL (3) | IL175523A (es) |
| NO (1) | NO20062672L (es) |
| NZ (1) | NZ546632A (es) |
| PE (3) | PE20090047A1 (es) |
| PL (1) | PL1694705T3 (es) |
| PT (1) | PT1694705E (es) |
| RS (1) | RS51180B (es) |
| SG (1) | SG155205A1 (es) |
| SI (1) | SI1694705T1 (es) |
| WO (2) | WO2005047324A2 (es) |
| ZA (1) | ZA200603681B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002220257A1 (en) * | 2000-12-07 | 2002-06-18 | Board Of Regents, The University Of Texas System | Methods of treatment involving human mda-7 |
| WO2002057283A1 (en) * | 2001-01-19 | 2002-07-25 | Baylor College Of Medecine | Methods and compositions in breast cancer diagnosis and therapeutics |
| US20040009939A1 (en) * | 2002-03-05 | 2004-01-15 | Board Of Regent, The University Of Texas System | Methods of enhancing immune induction involving MDA-7 |
| US8034790B2 (en) * | 2003-12-01 | 2011-10-11 | Introgen Therapeutics | Use of MDA-7 to inhibit pathogenic infectious organisms |
| ATE390893T1 (de) * | 2004-02-23 | 2008-04-15 | Synthes Gmbh | Knochenschraube |
| US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
| JP2008531481A (ja) * | 2005-02-08 | 2008-08-14 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 癌の治療のための、ｍｄａ−７を含む組成物および方法 |
| US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| CA2620802A1 (en) | 2005-08-31 | 2007-03-08 | Schering Corporation | Engineered anti-il-23 antibodies |
| WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
| US8063188B2 (en) * | 2006-09-05 | 2011-11-22 | Eli Lilly And Company | Anti-myostatin antibodies |
| KR20090088950A (ko) | 2006-12-14 | 2009-08-20 | 쉐링 코포레이션 | 가공된 항-ｔｓｌｐ 항체 |
| WO2008079352A2 (en) | 2006-12-22 | 2008-07-03 | Schering Corporation | Antibodies to cd200r |
| KR20090094154A (ko) | 2006-12-22 | 2009-09-03 | 쉐링 코포레이션 | Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
| EP2081922B1 (en) | 2006-12-22 | 2012-02-01 | Schering Corporation | 5,6-Ring annulated indole derivatives and use thereof |
| JP5211068B2 (ja) * | 2006-12-22 | 2013-06-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 |
| WO2008103473A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| KR101520110B1 (ko) | 2007-02-23 | 2015-05-18 | 머크 샤프 앤드 돔 코포레이션 | 가공된 항-ＩＬ-23ｐ19 항체 |
| MX2009009283A (es) | 2007-02-28 | 2009-11-18 | Schering Corp | Anticuerpos anti-interleuquina -23r de ingenieria. |
| BRPI0815811A2 (pt) | 2007-08-29 | 2015-02-18 | Schering Corp | Derivados de indol substituído e métodos de uso dos mesmos |
| BRPI0816116A2 (pt) * | 2007-08-29 | 2015-03-03 | Schering Corp | Derivados de indol 2,3-substituídos para o tratamento de infecções virais. |
| TW200911807A (en) | 2007-08-29 | 2009-03-16 | Schering Corp | 2,3-substituted azaindole derivatives and methods of use thereof |
| JP5416708B2 (ja) * | 2007-11-16 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法 |
| MX2010005356A (es) * | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| EP2303893B1 (en) * | 2008-06-13 | 2016-12-07 | Merck Sharp & Dohme Corp. | Tricyclic indole derivatives |
| EP2725037A1 (en) * | 2008-09-04 | 2014-04-30 | Vet Therapeutics, Inc. | Monoclonal antibodies binding canine CD20 |
| BRPI1005984A2 (pt) * | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| AU2010253791A1 (en) | 2009-05-29 | 2011-11-24 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C |
| EP3023438B1 (en) | 2009-09-03 | 2020-03-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
| CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| RU2581812C2 (ru) | 2009-11-30 | 2016-04-20 | Биотест Аг | Гуманизированные антитела против il-10 для лечения системной красной волчанки (sle) |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| US9433621B2 (en) | 2010-02-18 | 2016-09-06 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| WO2011112429A1 (en) | 2010-03-09 | 2011-09-15 | Schering Corporation | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| WO2011160119A2 (en) | 2010-06-19 | 2011-12-22 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| EP2598149A4 (en) | 2010-07-26 | 2014-09-10 | Merck Sharp & Dohme | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES |
| AU2011314168A1 (en) | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| UY33743A (es) * | 2010-11-23 | 2012-06-29 | Glaxo Group Ltd | Proteínas de unión a antígenos |
| EP3604339B1 (en) | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| KR20130138840A (ko) | 2011-04-13 | 2013-12-19 | 머크 샤프 앤드 돔 코포레이션 | 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법 |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| CN102250243B (zh) * | 2011-07-01 | 2013-08-28 | 华绍炳 | 抗白细胞介素-15抗体 |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| US9512405B2 (en) | 2011-12-14 | 2016-12-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Non-enzymatic method for isolating human adipose-derived stromal stem cells |
| CN105705165B (zh) | 2013-03-15 | 2020-04-24 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CN105277638A (zh) * | 2014-07-22 | 2016-01-27 | 沈鹤霄 | 一种单克隆抗体IgG质谱测序方法 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CA2986232A1 (en) * | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer |
| JP6893608B2 (ja) * | 2015-05-29 | 2021-06-23 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用 |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
| EP3394099A4 (en) * | 2015-12-22 | 2019-11-27 | Merck Sharp & Dohme Corp. | Formulations of Manipulated Anti- IL-10 Antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
| WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
| WO2019179420A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-tim-3 antibodies |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| WO2021072225A1 (en) * | 2019-10-09 | 2021-04-15 | Rush University Medical Center | Modulating interleukin-10 signaling to boost healing in diabetic wounds |
| JP2023549872A (ja) | 2020-11-18 | 2023-11-29 | アストラゼネカ・アクチエボラーグ | ステロイド節約 |
| CN118043349B (zh) * | 2021-06-11 | 2024-11-15 | 丰华生物有限公司 | 一种人源化抗人GPVI单克隆抗体Fab片段及其应用 |
| EP4608450A1 (en) * | 2022-10-24 | 2025-09-03 | Merck Sharp & Dohme LLC | Human hyaluronidase 1 mutants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| US6312680B1 (en) | 1990-06-29 | 2001-11-06 | Timothy R. Mosmann | Methods of treatment using cytokine synthesis inhibitory factor |
| WO1992022653A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1993002693A2 (en) * | 1991-08-06 | 1993-02-18 | Schering Corporation | Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CZ283488B6 (cs) * | 1992-08-20 | 1998-04-15 | Schering Corporation | Farmaceutický prostředek obsahující IL-4 a/nebo IL-10 nebo protilátky proti IL-4 a IL-10, způsob jeho výroby a jeho použití |
| DE19529026C2 (de) * | 1995-07-28 | 1997-06-19 | Robert Sabat | Monoklonale Antikörper gegen humanes Interleukin-10 |
| WO2001054732A1 (en) * | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| CN1671416B (zh) * | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| JP4347694B2 (ja) * | 2001-10-16 | 2009-10-21 | レイベン バイオテクノロジーズ，インコーポレイティド | 癌関連抗原ｃｄ４６に結合する抗体およびその使用方法 |
| DE60328195D1 (de) * | 2002-03-29 | 2009-08-13 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
-
2004
- 2004-11-08 AR ARP040104114A patent/AR046833A1/es active IP Right Grant
- 2004-11-08 PE PE2008001585A patent/PE20090047A1/es not_active Application Discontinuation
- 2004-11-08 PE PE2004001085A patent/PE20050925A1/es active IP Right Grant
- 2004-11-08 WO PCT/US2004/037013 patent/WO2005047324A2/en not_active Ceased
- 2004-11-08 PE PE2008001584A patent/PE20090046A1/es not_active Application Discontinuation
- 2004-11-09 CN CN2010100045818A patent/CN102010471A/zh active Pending
- 2004-11-09 KR KR1020127001620A patent/KR20120025618A/ko not_active Abandoned
- 2004-11-09 EP EP04810674A patent/EP1694705B1/en not_active Expired - Lifetime
- 2004-11-09 AT AT04810674T patent/ATE440867T1/de active
- 2004-11-09 DE DE602004022855T patent/DE602004022855D1/de not_active Expired - Lifetime
- 2004-11-09 WO PCT/US2004/037518 patent/WO2005047326A2/en not_active Ceased
- 2004-11-09 KR KR1020127001612A patent/KR20120023858A/ko not_active Ceased
- 2004-11-09 AU AU2004290044A patent/AU2004290044B2/en not_active Expired
- 2004-11-09 DK DK04810674T patent/DK1694705T3/da active
- 2004-11-09 PT PT04810674T patent/PT1694705E/pt unknown
- 2004-11-09 EP EP09010835A patent/EP2123678A1/en not_active Withdrawn
- 2004-11-09 RS RSP-2009/0439A patent/RS51180B/sr unknown
- 2004-11-09 CA CA2545255A patent/CA2545255C/en not_active Expired - Lifetime
- 2004-11-09 US US10/985,584 patent/US20050101770A1/en not_active Abandoned
- 2004-11-09 JP JP2006539809A patent/JP4762148B2/ja not_active Expired - Lifetime
- 2004-11-09 NZ NZ546632A patent/NZ546632A/en not_active IP Right Cessation
- 2004-11-09 SG SG200905318-2A patent/SG155205A1/en unknown
- 2004-11-09 SI SI200431289T patent/SI1694705T1/sl unknown
- 2004-11-09 EP EP10013136A patent/EP2292661A3/en not_active Withdrawn
- 2004-11-09 ES ES04810674T patent/ES2329907T3/es not_active Expired - Lifetime
- 2004-11-09 CA CA2812856A patent/CA2812856A1/en not_active Abandoned
- 2004-11-09 EP EP09010836A patent/EP2128175A1/en not_active Ceased
- 2004-11-09 CN CN200480040148A patent/CN100595212C/zh not_active Expired - Lifetime
- 2004-11-09 HR HR20090517T patent/HRP20090517T1/xx unknown
- 2004-11-09 PL PL04810674T patent/PL1694705T3/pl unknown
-
2006
- 2006-05-09 IL IL175523A patent/IL175523A/en active IP Right Grant
- 2006-05-09 ZA ZA200603681A patent/ZA200603681B/xx unknown
- 2006-05-10 KR KR1020067009074A patent/KR101175055B1/ko not_active Expired - Lifetime
- 2006-06-09 NO NO20062672A patent/NO20062672L/no not_active Application Discontinuation
-
2007
- 2007-01-12 US US11/623,006 patent/US7662379B2/en not_active Expired - Lifetime
-
2009
- 2009-10-20 CY CY20091101088T patent/CY1110557T1/el unknown
- 2009-12-10 IL IL202682A patent/IL202682A0/en active IP Right Grant
- 2009-12-10 IL IL202681A patent/IL202681A/en active IP Right Grant
- 2009-12-17 AR ARP090104951A patent/AR074780A2/es not_active Application Discontinuation
- 2009-12-17 AR ARP090104950A patent/AR074779A2/es unknown
-
2010
- 2010-02-05 US US12/701,386 patent/US8226947B2/en not_active Expired - Lifetime
- 2010-11-30 JP JP2010267846A patent/JP2011062211A/ja not_active Withdrawn
- 2010-11-30 JP JP2010267845A patent/JP2011087590A/ja not_active Withdrawn
-
2011
- 2011-02-14 AU AU2011200606A patent/AU2011200606B2/en not_active Ceased
-
2012
- 2012-07-19 US US13/553,554 patent/US8624013B2/en not_active Expired - Lifetime
-
2013
- 2013-07-24 JP JP2013153356A patent/JP2014014361A/ja not_active Withdrawn
- 2013-12-23 US US14/138,486 patent/US20140112919A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090047A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| CL2020001575A1 (es) | Anticuerpos anti-trem2 y métodos relacionados. | |
| MX2021000931A (es) | Determinación de modificaciones de bases de ácidos nucleicos. | |
| Veres et al. | Strategically positioned inhibitory synapses of axo-axonic cells potently control principal neuron spiking in the basolateral amygdala | |
| AR065420A1 (es) | Anticuerpos anti-il-23 p19 de ingenieria | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| CR9393A (es) | Anticuerpos anti-ccr5 y usos de los mismos | |
| CY1117702T1 (el) | Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη | |
| ATE408684T1 (de) | Verfahren zur verbesserung von t-zellrezeptoren | |
| CY1107669T1 (el) | Απλης αλυσου vhh αντισωματα καμηλοειδους και μεθοδος για την παρασκευη αυτου σε ενα θηλαστικο | |
| AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| DE602005020956D1 (de) | Verfahren und gerät zur identifikation von lebendigen eiern mittels pulsfrequenz und embryobewegung | |
| ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| EA201070888A1 (ru) | Антитела и их производные | |
| ATE492563T1 (de) | Vollständige humane monoklonale antikörper gegen il-13 | |
| UY29288A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
| DE60320828D1 (de) | Fret proben und verfahren zur erkennung aufeinander einwirkeneden moleküle | |
| EA201390453A1 (ru) | Человеческие анти-тау антитела | |
| AR108717A1 (es) | Anticuerpos antifactor de la coagulación xi | |
| PE20050627A1 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloideo | |
| ATE441102T1 (de) | Verfahren zur detektion von intrazellulären parametern mit lumineszierenden proteinsonden zur selektion von molekülen, die diese parameter ändern kínnen | |
| ATE447174T1 (de) | Verfahren zum direkten nachweis einzelner methotrexatmetabolite | |
| CL2022003299A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y usos | |
| DE112004001215D2 (de) | Handlampe, insbesondere für die magnetische Rissprüfung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |